SOPHiA GENETICS announced the University of Saskatchewan as its first HRD customer in Canada. USask will implement the SOPHiA DDM Platform for use in its cutting-edge clinical trial, which aims to substantially improve the quality of life for ovarian cancer patients through expanded genetic testing, the company said in a statement, adding that this is the first clinical trial in Canada designed to improve ovarian cancer treatment decisions and inspire guideline changes to increase access to advanced testing. “Using genetic testing to uncover tumor mutations and support treatment planning for cancer patients is a perfect example of precision medicine in practice. It’s exactly what we at SOPHiA GENETICS are working so hard to make available to clinician researchers around the world,” said John Carey, Managing Director, NORAM, SOPHiA GENETICS.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SOPH: